Neuroendocrine tumours: The role of imaging for diagnosis and therapy

Nature Reviews Endocrinology

Volumn 10, Issue 2, 2014, Pages 102-114

  Van Essen, Martijn ^a   Sundin, Anders ^b   Krenning, Eric P ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; HUMAN; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; TUMOR SCINTISCANNING;

DIAGNOSTIC IMAGING; HUMANS; INTESTINAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84892956395     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.246     Document Type: Review

References (107)

1. Rindi, G. et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 449, 395-401 (2006).
2. Rindi, G. et al. TNM staging of midgut and hindgut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 451, 757-762 (2007).
3. Hamilton, S. R. & Aaltonen, L. A. (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System (IARC Press, Lyon, 2000).
4. Bilimoria, K. Y. et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: Analysis of 9,821 patients. J. Gastrointest. Surg. 11, 1460-1467 (2007).
5. Bergsma, H. et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract. Res. Clin. Gastroenterol. 26, 867-881 (2012).
6. Sundin, A., Garske, U. & Orlefors, H. Nuclear imaging of neuroendocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab. 21, 69-85 (2007).
7. Sundin, A., Vullierme, M. P., Kaltsas, G. & Plöckinger, U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Radiological examinations. Neuroendocrinology 90, 167-183 (2009).
8. Sundin, A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 803-818 (2012).
9. Masselli, G. & Gualdi, G. CT and MR enterography in evaluating small bowel diseases: when to use which modality Abdom. Imaging 38, 249-259 (2013).
10. Bailey, A. A. et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: A three-center Australian experience. Am. J. Gastroenterol. 101, 2237-2243 (2006).
11. Gallotti, A. et al. Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. AJR Am. J. Roentgenol. 200, 355-362 (2013).
12. Poultsides, G. A. et al. Pancreatic neuroendocrine tumors: Radiographic calcifications correlate with grade and metastasis. Ann. Surg. Oncol. 19, 2295-2303 (2012).
13. Ishikawa, T. et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest. Endosc. 71, 951-959 (2010).
14. Khashab, M. A. et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest. Endosc. 73, 691-696 (2011).
15. Versari, A. et al. Ga-68 DOTA-TOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: A single-centre retrospective study. Clin. Nucl. Med. 35, 321-328 (2010).
16. Atiq, M. et al. EUS-FNA for pancreatic neuroendocrine tumors: A tertiary cancer center experience. Dig. Dis. Sci. 57, 791-800 (2012).
17. Pais, S. A. et al. EUS for pancreatic neuroendocrine tumors: A single-center, 11-year experience. Gastrointest. Endosc. 71, 1185-1193 (2010).
18. Stark, D. D., Moss, A. A., Goldberg, H. I. & Deveney, C. W. CT of pancreatic islet cell tumors. Radiology 150, 491-494 (1984).
19. Rossi, P. et al. CT of functioning tumors of the pancreas. AJR Am. J. Roentgenol. 144, 57-60 (1985).
20. Van Hoe, L., Gryspeerdt, S., Marchal, G., Baert, A. L. & Mertens, L. Helical CT for the preoperative localization of islet cell tumors of the pancreas: Value of arterial and parenchymal phase images. AJR Am. J. Roentgenol. 165, 1437-1439 (1995).
21. Procacci, C. et al. Nonfunctioning endocrine tumors of the pancreas: Possibilities of spiral CT characterization. Eur. Radiol. 11, 1175-1183 (2001).
22. Fidler, J. L. et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am. J. Roentgenol. 181, 775-780 (2003).
23. Chiti, A. et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastroenteropancreatic tumours. Eur. J. Nucl. Med. 25, 1396-1403 (1998).
24. Kumbasar, B. et al. Imaging of neuroendocrine tumors: Accuracy of helical CT versus SRS. Abdom. Imaging 29, 696-702 (2004).
25. Hubalewska-Dydejczyk, A. et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience. Eur. J. Nucl. Med. Mol. Imaging 33, 1123-1133 (2006).
26. Cwika, J. B. et al. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med. Sci. Monit. 10 (Suppl. 3), 9-16 (2004).
27. Thoeni, R. F., Mueller-Lisse, U. G., Chan, R., Do, N. K. & Shyn, P. B. Detection of small, functional islet cell tumors in the pancreas: Selection of MR imaging sequences for optimal sensitivity. Radiology 214, 483-490 (2000).
28. Semelka, R. C., Custodio, C. M., Cem Balci, N. & Woosley, J. T. Neuroendocrine tumors of the pancreas: Spectrum of appearances on MRI. J. Magn. Reson. Imaging 11, 141-148 (2000).
29. Shi, W. et al. Localization of neuroendocrine tumours with [111In]DTPAoctreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging. QJM 91, 295-301 (1998).
30. Carlson, B., Johnson, C. D., Stephens, D. H., Ward, E. M. & Kvols, L. K. MRI of pancreatic islet cell carcinoma. J. Comput. Assist. Tomogr. 17, 735-740 (1993).
31. Dromain, C. et al. Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol. 23, 70-78 (2005).
32. Elias, D. et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: They are many more than you think. Ann. Surg. 251, 307-310 (2010).
33. Rahmim, A. & Zaidi, H. PET versus SPECT: Strengths, limitations and challenges. Nucl. Med. Commun. 29, 193-207 (2008).
34. Khalil, M. M., Tremoleda, J. L., Bayomy, T. B. & Gsell, W. Molecular SPECT imaging: An overview. Int. J. Mol. Imaging 2011, 796025 (2011).
35. Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N. & Shapiro, M. D. Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717-1751 (2005).
36. Reubi, J. C., Waser, B., Schaer, J. C. & Laissue, J. A. Somatostatin receptor SST1-SST5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836-846 (2001).
37. Virgolini, I. et al. In- and YDOTAlanreotide: Results and implications of the MAURITIUS trial. Semin. Nucl. Med. 32, 148-155 (2002).
38. Lebtahi, R. et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J. Nucl. Med. 43, 889-895 (2002).
39. Koopmans, K. P. et al. Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. Crit. Rev. Oncol. Hematol. 71, 199-213 (2009).
40. Bombardieri, E. et al. 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 37, 1441-1448 (2010).
41. Balon, H. R. et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J. Nucl. Med. Technol. 39, 317-324 (2011).
42. Modlin, I. M. & Tang, L. H. Approaches to the diagnosis of gut neuroendocrine tumors: The last word (today). Gastroenterology 112, 583-590 (1997).
43. Kaplan, E. L. & Lee, C. H. Recent advances in the diagnosis and treatment of insulinomas. Surg. Clin. North Am. 59, 119-129 (1979).
44. Wild, D. et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J. Nucl. Med. 52, 1073-1078 (2011).
45. Reubi, J. C. & Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781-793 (2003).
46. Wild, D., Macke, H., Christ, E., Gloor, B. & Reubi, J. C. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N. Engl. J. Med. 359, 766-768 (2008).
47. Christ, E. et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 94, 4398-4405 (2009).
48. Wild, D. et al. 'Running on empty'. Eur. J. Nucl. Med. Mol. Imaging 37, 1439-1440 (2010).
49. Lu, S. J., Gnanasegaran, G., Buscombe, J. & Navalkissoor, S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: A review of the literature. Nucl. Med. Commun. 34, 98-107 (2013).
50. Christenson, J. G., Dairman, W. & Udenfriend, S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic l-amino acid decarboxylaseserotonindopaminenorepinephrine). Proc. Natl Acad. Sci. USA 69, 343-347 (1972).
51. Orlefors, H. et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C5-hydroxytryptophan positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33, 60-65 (2006).
52. National Nuclear Data Center. Nuclear structure and decay data [online], http://www.nndc.bnl.gov/nudat2/reCenter.jspz=6&n=5 (2013).
53. Hofland, L. J. & Lamberts, S. W. Somatostatin receptor subtype expression in human tumors. Ann. Oncol. 12 (Suppl. 2), S31-S36 (2001).
54. Eriksson, B. et al. Developments in PET for the detection of endocrine tumours. Best Pract. Res. Clin. Endocrinol. Metab. 19, 311-324 (2005).
55. Timmers, H. J. et al. The effects of carbidopa on uptake of 618FFluoroLDOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J. Nucl. Med. 48, 1599-1606 (2007).
56. Kauhanen, S., Seppänen, M. & Nuutila, P. Premedication with carbidopa masks positive finding of insulinoma and -cell hyperplasia in [18F]dihydroxyphenyl-alanine positron emission tomography. J. Clin. Oncol. 26, 5307-5308 (2008).
57. Antunes, P. et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals Eur. J. Nucl. Med. Mol. Imaging 34, 982-993 (2007).
58. Treglia, G., Castaldi, P., Rindi, G., Giordano, A. & Rufini, V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis. Endocrine 42, 80-87 (2012).
59. Freudenberg, L. S, Rosenbaum, S. J., Beyer, T., Bockisch, A. & Antoch, G. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol. Clin. North Am. 45, 639-644 (2007).
60. Breeman, W. A. et al. 68Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin. Nucl. Med. 41, 314-321 (2011).
61. Ambrosini, V., Campana, D., Tomassetti, P. & Fanti, S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur. J. Nucl. Med. Mol. Imaging 39, S52-S60 (2012).
62. Virgolini, I. et al. Procedure guidelines for PET/CT tumour imaging with 68GaDOTAconjugated peptides: 68GaDOTATOC, 68GaDOTANOC, 68GaDOTATATE. Eur. J. Nucl. Med. Mol. Imaging 37, 2004-2010 (2010).
63. Ambrosini, V. et al. Comparison between 68GaDOTANOC and 18F-DOPA PET for the detection of gastroenteropancreatic and lung neuro-endocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35, 1431-1438 (2008).
64. Haug, A. et al. Intraindividual comparison of 68GaDOTATATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36, 765-770 (2009).
65. Putzer, D. et al. Comparison of (68)GaDOTATyr(3)-octreotide and (18)FfluoroL-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q. J. Nucl. Med. Mol. Imaging 54, 68-75 (2010).
66. Binderup, T. et al. Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: Correlation with F18fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics 3, 372-384 (2013).
67. Pasquali, C. et al. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior World J. Surg. 22, 588-592 (1998).
68. Binderup, T. et al. Functional imaging of neuroendocrine tumors: A headtohead comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J. Nucl. Med. 51, 704-712 (2010).
69. Adams, S. et al. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen. Nucl. Med. Commun. 19, 641-647 (1998).
70. Ambrosini, V., Fani, M., Fanti, S., Forrer, F. & Maecke, H. R. Radiopeptide imaging and therapy in Europe. J. Nucl. Med. 52, 42S-55S (2011).
71. Teunissen, J. J., Kwekkeboom, D. J., Valkema, R. & Krenning, E. P. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr. Relat. Cancer 18, S27-S51 (2011).
72. Hofmann, M. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur. J. Nucl. Med. 28, 1751-1757 (2001).
73. Kowalski, J. et al. Evaluation of positron emission tomography imaging using [68Ga]DOTAD Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5, 42-48 (2003).
74. Buchmann, I. et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 34, 1617-1626 (2007).
75. Srirajaskanthan, R. et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111InDTPAoctreotide scintigraphy. J. Nucl. Med. 51, 875-882 (2010).
76. Krausz, Y. et al. 68GaDOTANOC PET/CT imaging of neuroendocrine tumors: Comparison with InDTPAoctreotide (OctreoScan®) . Mol. Imaging Biol. 13, 583-593 (2011).
77. Hofman, M. S. et al. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J. Med. Imaging Radiat. Oncol. 56, 40-47 (2012).
78. Gabriel, M. et al. 68GaDOTATyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508-518 (2007).
79. Wild, D. et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 54, 364-372 (2013).
80. Poeppel, T. D. et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J. Nucl. Med. 52, 1864-1870 (2011).
81. Kabasakal, L. et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 39, 1271-1277 (2012).
82. Koopmans, K. P. et al. Staging of carcinoid tumours with 18F-DOPA PET: A prospective, diagnostic accuracy study. Lancet Oncol. 7, 728-734 (2006).
83. Koopmans, K. P. et al. Improved staging of patients with carcinoid and islet cell tumors with 18Fdihydroxyphenyl-alanine and 11C5hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. 26, 1489-1495 (2008).
84. Schiesser, M. et al. Value of combined 6-[18F] fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. Br. J. Surg. 97, 691-697 (2010).
85. Montravers, F. et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors J. Nucl. Med. 47, 1455-1462 (2006).
86. Yakemchuk, V. N. et al. PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nucl. Med. Commun. 33, 322-330 (2012).
87. Becherer, A. et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J. Nucl. Med. 45, 1161-1167 (2004).
88. Balogova, S. et al. 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur. J. Nucl. Med. Mol. Imaging 40, 943-966 (2013).
89. Orlefors, H. et al. Whole-body (11)C5hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J. Clin. Endocrinol. Metab. 90, 3392-3400 (2005).
90. Abgral, R. et al. Performance of 18fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (10%) well-differentiated endocrine carcinoma staging. J. Clin. Endocrinol. Metab. 96, 665-671 (2011).
91. Salazar, R. et al. ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: An update. Neuroendocrinology 95, 71-73 (2012).
92. Kvols, L. K. et al. The North American Neuroendocrine Tumor Society (NANETS) guidelines: Mission, goals, and process.Pancreas 39, 705-706 (2010).
93. Kwekkeboom, D. J. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology 90, 184-189 (2009).
94. Ito, T., Igarashi, H. & Jensen, R. T. Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances. Best Pract. Res. Clin. Gastroenterol. 26, 737-753 (2012).
95. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
96. Strosberg, J. R. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current approaches and future options. Endocr. Pract. http://dx.doi.org/10.4158/EP13262.RA.
97. Sundin, A. & Rockall, A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology 96, 261-271 (2012).
98. Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753-1759 (2007).
99. Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35, 1773-1782 (1999).
100. Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S-150S (2009).
101. Kwekkeboom, D. J. et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23, 2754-2762 (2005).
102. Haug, A. R. et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J. Nucl. Med. 51, 1349-1356 (2010).
103. Gabriel, M. et al. 68GaDOTATyr3-octreotide PET for assessing response to somatostatinreceptormediated radionuclide therapy. J. Nucl. Med. 50, 1427-1434 (2009).
104. Velikyan, I. et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl. Med. Biol. 37, 265-275 (2010).
105. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514-523 (2011).
106. Binderup, T., Knigge, U., Loft, A., Federspiel, B. & Kjaer, A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16, 978-985 (2010).
107. Severi, S. et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 40, 881-888 (2013).